Indication
Breast Cancer, Stage II
16 clinical trials
20 products
16 drugs
Clinical trial
A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03Status: Completed, Estimated PCD: 2021-12-25
Product
TX05Product
HerceptinClinical trial
Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express Human Epidermal Growth Factor Receptor 2 (HER-2)/NeuStatus: Terminated, Estimated PCD: 2010-11-18
Product
DoxorubicinDrug
cyclophosphamideDrug
bevacizumabDrug
paclitaxelProduct
GemcitabineDrug
pegfilgrastimClinical trial
A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-05-01
Drug
TiragolumabDrug
TrastuzumabClinical trial
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-08-29
Product
Dendritic Cell VaccineProduct
Neoadjuvant ChemotherapyClinical trial
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative SettingStatus: Active (not recruiting), Estimated PCD: 2018-06-01
Drug
T-DM1Product
PertuzumabClinical trial
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
MargetuximabClinical trial
Window of Opportunity Study Targeting the Inflammatory Milieu of Pregnancy Associated Breast CancerStatus: Active (not recruiting), Estimated PCD: 2014-01-14
Drug
CelecoxibClinical trial
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2022-08-04
Product
CyclophosphamideProduct
PaclitaxelProduct
CarboplatinProduct
DecitabineProduct
PembrolizumabClinical trial
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast CancerStatus: Recruiting, Estimated PCD: 2025-07-17
Product
NiraparibProduct
DostarlimabClinical trial
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
anastrozoleClinical trial
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent SimvastatinStatus: Terminated, Estimated PCD: 2017-04-25
Product
SimvastatinProduct
Doxorubicin/cyclophosphamideClinical trial
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2021-04-07
Drug
UTD1Drug
AN0025Drug
CisplatinClinical trial
A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast CancerStatus: Completed, Estimated PCD: 2007-05-01
Product
Darbepoetin AlfaProduct
PegfilgrastimDrug
R-CHOPClinical trial
A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant SettingStatus: Completed, Estimated PCD: 2021-07-01
Drug
AbraxaneClinical trial
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant SettingStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
TucidinostatProduct
Trastuzumab DeruxtecanClinical trial
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III StudyStatus: , Estimated PCD: 2025-08-31
Drug
fulvestrant